本帖最后由 老马 于 2012-1-13 21:20 编辑
' @% `( h; x; P' w# u) c& ]- Q" j; l4 ]# m' @
爱必妥和阿瓦斯丁的比较
$ c/ R0 A) O/ \: B. y$ m/ d6 X
! L7 `, y, [; f4 U, Ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/ J, T* D& d+ x) i* x7 s
5 c+ q% _1 u. q! q/ U2 A
, z8 _! J# D1 l$ v& @) Whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial// h8 }9 [5 }. P2 s5 C2 h
==================================================( Q9 p6 R, [7 [- N* w1 j
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ e( W2 M" q$ Y4 ^6 L5 mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 u R+ r0 D- J: h$ K4 {5 m2 fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, h3 ^, V$ E& ]9 k4 ~
|
显身卡
